CRISPR Therapeutics to Participate in Upcoming Investor Conferences
Rhea-AI Summary
CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company specializing in gene-based medicines, has announced its participation in two major investor conferences in September 2025.
The company will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8 at 4:30 p.m. ET and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9 at 8:30 a.m. ET. Live webcasts will be available on the company's website, with replays accessible for 14 days after the presentations.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, CRSP gained 1.60%, reflecting a mild positive market reaction. This price movement added approximately $79M to the company's valuation, bringing the market cap to $5.02B at that time.
Data tracked by StockTitan Argus on the day of publication.
ZUG, Switzerland and BOSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following investor conferences in September.
H.C. Wainwright 27th Annual Global Investment Conference
Date: Monday, September 8, 2025
Time: 4:30 p.m. ET
Morgan Stanley 23rd Annual Global Healthcare Conference
Date: Tuesday, September 9, 2025
Time: 8:30 a.m. ET
A live webcast will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcasts will be archived on the Company's website for 14 days following the presentation.
About CRISPR Therapeutics
Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the first-ever CRISPR-based therapy. The Company has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia. Beginning in late 2023, CASGEVY® (exagamglogene autotemcel [exa-cel]) was approved in several countries to treat eligible patients with either of these conditions. The Nobel Prize-winning CRISPR technology has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has formed strategic partnerships with leading companies including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California. To learn more, visit www.crisprtx.com.
Investor Contact:
+1-617-307-7503
ir@crisprtx.com
Media Contact:
+1-617-315-4493
media@crisprtx.com
FAQ
When is CRISPR Therapeutics (CRSP) presenting at the Morgan Stanley Healthcare Conference 2025?
How can I watch CRISPR Therapeutics' (CRSP) conference presentations in September 2025?
What investor conferences is CRISPR Therapeutics (CRSP) attending in September 2025?
What time is CRISPR Therapeutics' (CRSP) presentation at the H.C. Wainwright Conference?
